Biogen (NASDAQ:BIIB) plummeted in the pre-market after a West Virginia judge found that generic drug maker Mylan (NASDAQ:MYL) demonstrated Biogen’s U.S. patent ‘514 for Tecfidera was “invalid for lack of written description.”
Tecfidera was approved for treatment of multiple sclerosis and Mylan sought to market a bioequivalent.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.